Video summary

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy? | LLY Stock Analysis

Main summary

Key takeaways

Finance

Market / Stock Context (LLY)

  • Eli Lilly (LLY) has rallied over recent months but is still ~up 4% year-to-date (YTD).
  • The stock recovered from ~$850 (early May) to ~$1,115.

Company Growth Drivers & Pipeline / Catalysts

Investors are drawn to Lilly’s ability to innovate beyond its weight-loss franchise—not just buying the story as a weight-loss beneficiary.

Jaypirca (Phase 3)

  • Positive Phase 3 results in relapsed/refractory chronic lymphocytic leukemia.
  • Reported a 45% reduction in risk of disease progression or death.

Retatrutide (Phase 3)

  • Phase 3 promise for weight loss / obesity-related conditions:
    • Patients average >28% weight loss over 80 weeks
    • Improvements across multiple obesity-related health conditions
  • Rationale cited includes:
    • Better efficacy
    • Addressing tolerability
    • Improving delivery/distribution effectiveness

Financial Performance Metrics Highlighted

  • Operating profit margin
    • ~10% in 2017
    • >40% in the most recently completed year
  • Cash flow from operations (CFO) to sales ratio
    • Ended at 25.8%
    • Described as near the higher end of the past decade range

Key emphasis: investors should look for R&D that converts into profits and cash flow, not only revenue.

Valuation (Multiples + DCF)

Market Multiples

  • Forward P/E: 30
  • Forward P/Operating Cash Flow: 29.4
  • Used as a sanity check against market norms for the company’s growth and margin profile.

Discounted Cash Flow (DCF)

  • Fair value estimate: $1,443
  • Current market price: ~$1,114
  • Implied upside: about $329 (~29%)
  • Presenter notes the DCF fair value has been moving higher as weight-loss sales/profits/CFO come in better than expected.

Risk Discussion & Portfolio Construction Angle

Macro correlation / diversification claim

  • Pharmaceutical demand is presented as less correlated with the macroeconomy (health needs persist regardless of cycles), unlike more cyclical sectors such as automotive.

Beta adjustment (risk management)

  • Lilly is described as having extremely low beta, which may understate risk due to low correlation vs the S&P 500.
  • The presenter applies a beta multiplier of 1.5 to adjust risk upward.

Portfolio implication

  • Lilly may offer risk diversification because of lower correlation.
  • Particularly framed as useful for investors highly exposed to the AI trade:
    • The argument is that adding Lilly could increase portfolio robustness via an “uncorrelated return stream.”

Explicit Recommendations / Conclusions

  • Presenter conclusion: Eli Lilly is still an excellent stock to buy.
  • Valuation stance: “undervalued” using both market multiples and DCF.

Disclosures / Disclaimers

  • The video includes a sponsored segment: The Motley Fool.
  • No explicit “not financial advice” disclaimer was included in the provided subtitles excerpt.

Tickers / Instruments Mentioned

  • LLY — Eli Lilly
  • S&P 500 — benchmark referenced for beta/correlation
  • References to “AI stocks” / “AI trade” (no specific tickers mentioned)
  • Car companies referenced as examples (no tickers mentioned)

Methodology / Framework (Step-by-Step Style)

  1. Valuation via market multiples
    • Use forward P/E and forward P/Operating Cash Flow as a sanity check.
  2. Valuation via DCF
    • Compute a fair value estimate, compare it to current price, and track changes as weight-loss performance improves (sales/profits/CFO).
  3. Risk adjustment using beta
    • Treat low beta (low correlation to S&P 500) as potentially understating risk.
    • Apply a beta multiplier of 1.5 for a more conservative risk view.

Presenters / Sources

  • Motley Fool (sponsor mention: “Visit fool.com/parkev…”)
  • No individual presenter name is provided in the subtitles excerpt.

Original video